Inpatient Infliximab Biosimilar Cost-Savings - Cost analysis of inpatient treatment with originator Infliximab (Remicade™) vs biosimilar Infliximab (Renflexis™) for acute severe ulcerative colitis. .

No differences were found in baseline or discharge clinical parameters. Median unadjusted ratio of DSDC to total inpatient cost of care was 0.387 vs. 0.241 in the Remicade vs. Renflexis groups (p=0.0025), respectively, representing an absolute difference of ~14%. Median adjusted rDSDC was 0.04 vs. 0.024 in the Remicade vs. Renflexis groups, respectively, representing a relative cost reduction of ~40% (p = 0.0001) Discussion: The unadjusted absolute cost reduction and adjusted relative cost reduction were respectively 14% and 40% in the Renflexis group as compared to Remicade. Our calculation included median decision support drug cost as a percentage of the total inpatient cost of care, controlling for infliximab dose and length of stay. This reduced cost structure promotes use of Renflexis for ASUC inpatients and may reduce costs for patients and hospitals.